TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02864719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Conservation+Problem Solving Therapy
Description: The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
Study: NCT01974154

Intervention type: OTHER
Intervention: Cohort I
Description: We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
Study: NCT03501706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal Memory--Visual
Description: word recognition AT memory component
Study: NCT01974154

Intervention type: OTHER
Intervention: Cohort II
Description: Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
Study: NCT03896685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 100 MG
Description: Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
Study: NCT04964830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with functional appliance (MAD)
Description: Expansion plate and z-activator (MAD)
Study: NCT04598165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive two-way SMS dialogue
Description: We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
Study: NCT03896685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid 50 MG Oral Tablet
Description: Delamanid: 100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 MG Oral Capsule
Description: Clofazimine: 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600Mg Tab
Description: Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm MDR-TB regimen, designed according to latest WHO guidelines
Description: Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
Study: NCT03029273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Fludarabine
Description: Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY-ESO-1 TCR transduced T cells
Description: A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
Study: NCT00187031

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan, Filgrastim (G-CSF), Pegfilgrastim
Description: See detailed description section for additional details.
Study: NCT02101203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mgTestosterone + 10 mg Buspirone
Description: A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).
Study: NCT04149873

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MIE
Description: MIE

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MIE
Description: MIE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIE
Description: MIE
Study: NCT01962831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single balloon foley catheter
Study: NCT02001181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib ointment 20mg/g
Description: Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment (Vehicle)
Description: Placebo ointment (vehicle) twice daily (BID) for 4 weeks
Study: NCT04483323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular Injection
Description: Intraarticular injection of local anesthetic through the surgical port
Study: NCT02534220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating toothbrush
Description: Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
Study: NCT01931332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block with levobupivicaine
Description: A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal injection of diamorphine
Description: 500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
Study: NCT04461288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media-based education, counseling, and support
Description: This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media-based education, counseling, and support
Description: This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapies (NRT)
Description: Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapies (NRT)
Description: Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapies (NRT)
Description: Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Gaming elements designed to encourage participation in the program and behavior change.
Study: NCT00756015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Motion Protocol
Description: Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Immobilization
Description: Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
Study: NCT00625794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Description: 8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: 8 weeks or counseling
Study: NCT02091973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus dosing to target tough level 6-10 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus dosing to target tough level 5-10 ng/ml
Study: NCT03648827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study: NCT03132012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor tanning intervention
Description: 6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
Study: NCT03038919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Bi-weekly intramuscular injection of testosterone cypionate 200mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard nutrition and physical therapy at ICU
Description: follow-up of the patient without use of testosterone cypionate
Study: NCT03132012

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care control
Description: One website with content similar to those available in dermatology offices on skin cancer prevention
Study: NCT02027376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03654066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botox injection in the LES

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botox injection in the LES

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscope balloon dilator
Description: Distal esophageal dilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcomes
Description: Subjects will complete two patient reported outcome measures (Eckardt and MADS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcomes
Description: Subjects will complete two patient reported outcome measures (Eckardt and MADS).
Study: NCT03038919

Intervention type: OTHER
Group type: OTHER
Intervention: Standard nutrition and physical therapy at ICU
Description: follow-up of the patient without use of testosterone cypionate
Study: NCT03654066

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Barium esophagram
Description: Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Barium esophagram
Description: Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
Study: NCT03283956

Intervention type: DEVICE
Intervention: Patient records
Description: Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
Study: NCT03848104

Intervention type: OTHER
Intervention: bone and joint infection treated with cefoxitin
Description: the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
Study: NCT01782911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: The patients will take 2 g of resveratrol per day for 40 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: The patients will take placebo for 40 days.
Study: NCT04115254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator
Study: NCT02994706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Care
Description: Participants selected for this arm will continue to receive routine clinical care.
Study: NCT03810885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced salt content
Description: Bread with gradually lowered salt content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced salt content
Description: Bread with gradually lowered salt content
Study: NCT04115254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator
Study: NCT04379271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
Study: NCT04655976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Cobolimab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered.
Study: NCT03260322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous
Study: NCT03810885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Participants will receive information on how to lower salt and increase potassium intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bread with standard salt content
Description: Bread with normal salt content
Study: NCT02808377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Pelvic Organ Pessary
Description: In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
Study: NCT02572609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride soft pastille